---
title: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870949/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231024180819&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Combination therapy with nivolumab plus gemcitabine-cisplatin
  resulted in significantly better outcomes in patients with previously untreated
  advanced urothelial carcinoma than gemcitabine-cisplatin alone. (Funded by Bristol
  Myers Squibb and Ono Pharmaceutical; CheckMate 901 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes in patients with previously untreated advanced urothelial carcinoma than gemcitabine-cisplatin alone. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 901 ClinicalTrials.gov number, ...